Zenas BioPharma, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Zenas BioPharma, Inc. (ZBIO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $19.35 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Zenas BioPharma, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $22.68, a 211.54% increase year-over-year.
- Zenas BioPharma, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $7.28.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month |
|---|---|---|---|
| 2026-06-30 | $19.35 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $22.68 10-Q · filed 2026-05-13 | ||
| 2025-09-30 | $10.82 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $10.66 10-Q · filed 2025-08-12 | ||
| 2025-03-31 | $7.28 10-Q · filed 2025-05-15 |